United States — Food and Drug Administration & Marty Makary
25 shared events · Importance 4 · Last updated Sep 08, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Domestic
United States — Food and Drug Administration: The FDA is the agency being led. It faces staff losses, morale issues, and policy controversies; Overton's nomination could exacerbate these challenges.
Marty Makary: Makary resigned as FDA commissioner in May after clashes with the White House. His departure created the vacancy Overton is nominated to fill.
Aug 19, 2026 · 101 articles
Regulatory
United States — Food and Drug Administration: The FDA gains permanent leadership in key centers, restoring stability after months of turnover. This affects its regulatory operations and relationships with regulated industries.
Marty Makary: Makary's resignation as FDA Commissioner in May contributed to the leadership upheaval; his policies on vaccines and tobacco drew criticism.
Sep 08, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA, under Commissioner Marty Makary, enacted regulations to phase out petroleum-based food dyes, driving the industry's shift. Its actions create regulatory pressure that affects all food companies.
Marty Makary: As FDA Commissioner, Makary enacted regulations to phase out synthetic dyes and linked them to health risks, catalyzing the industry's move toward natural colors.
Aug 26, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.
Marty Makary: Makary, former FDA Commissioner, faced criticism for vaccine scrutiny and resigned amid controversies.
Aug 05, 2026 · 105 articles
Regulatory
United States — Food and Drug Administration: The FDA is the subject of the restructuring, which could reshape its leadership and regulatory approach, affecting drug approvals and AI oversight.
Marty Makary: Makary's resignation in May created the leadership vacuum that led to the current restructuring.
Aug 25, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The agency at the center of the nomination, facing leadership change and policy shifts on vaccines, mifepristone, and vaping; it has lost about 20 percent of staff since Trump took office.
Marty Makary: Previous FDA commissioner who resigned in May after a tenure marked by scientific disputes and low morale; Overton studied under him at Johns Hopkins.
Sep 24, 2026 · 12 articles
Regulatory
United States — Food and Drug Administration: Regulatory body that approved Lipfendra, enabling market entry.
Marty Makary: Former FDA chief who created the accelerated review pathway used for Lipfendra; resigned in May 2026.
Jul 16, 2026 · 93 articles
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Marty Makary: Former FDA Commissioner Marty Makary initiated the Commissioner's National Priority Voucher Program, under which the drug was reviewed, contributing to the expedited approval.
Aug 26, 2026 · 92 articles
Domestic
United States — Food and Drug Administration: The FDA is mentioned as another agency with a leadership vacancy, but it is not directly involved in this event.
Marty Makary: Makary's resignation as FDA commissioner contributed to the leadership vacuum in health agencies.
Jul 15, 2026 · 148 articles
Business
United States — Food and Drug Administration: The FDA granted Breakthrough Therapy Designation to BPL-003 and announced regulatory actions to support psychedelic drug development, facilitating the path to market.
Marty Makary: Marty Makary, former FDA commissioner, commented on the FDA's regulatory actions supporting psychedelic therapeutics.
Jul 16, 2026 · 25 articles
Regulatory
Marty Makary: As Food and Drug Commissioner, Marty Makary signaled the administration's stance on saturated fats and commented on protein guidance.
Jan 07, 2026 · 7 articles
Regulatory
Marty Makary: As the Commissioner of the United States — Food and Drug Administration, Marty Makary is a key figure in implementing the new policy to reduce the number of required studies for drug approval, aiming to speed up drug development.
Feb 18, 2026 · 6 articles
International
Marty Makary: Marty Makary is resigning as the head of the United States — Food and Drug Administration due to difficulties and complaints from health industry executives, anti-abortion activists, and other Trump allies.
May 12, 2026 · 18 articles
International
Marty Makary: Marty Makary resigned as the head of the United States — Food and Drug Administration after a rocky tenure and complaints from various industry groups.
Apr 16, 2026 · 760 articles
Regulatory
Marty Makary: Marty Makary resigned as United States — Food and Drug Administration Commissioner, having engineered Tracy Beth Høeg's rapid rise and facing criticism from political allies.
May 15, 2026 · 17 articles
International
Marty Makary: Marty Makary resigned as the United States — Food and Drug Administration Commissioner, contributing to the agency's leadership upheavals.
May 12, 2026 · 17 articles
Domestic
Marty Makary: Marty Makary resigned as head of the United States — Food and Drug Administration, widening the leadership gap within the United States — United States Department of Health and Human Services and leaving behind unfinished initiatives.
May 13, 2026 · 6 articles
Domestic
Marty Makary: Marty Makary>>> resigned as Commissioner of the United States — Food and Drug Administration>>> after a tumultuous tenure marked by clashes with the Donald Trump>>> administration, industry, and public health groups. His departure creates uncertainty for several of his initiatives.
May 08, 2026 · 114 articles
International
Marty Makary: Marty Makary is resigning as the head of the United States — Food and Drug Administration after a rocky tenure, drawing complaints from various industry executives and activists.
Apr 30, 2026 · 116 articles
Regulatory
Marty Makary: Former United States — Food and Drug Administration Commissioner Marty Makary had indicated that reviewing the benefits of MDMA and other psychedelics was a top priority, though his resignation may impact the pace of review.
May 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Marty Makary interact across events, view sentiment trends, and discover connected entities.
Open Dashboard